Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.

摘要: Background Anagrelide is a quinazolin compound developed initially as an inhibitor of platelet aggregation. Since "in vivo" studies demonstrated that it was responsible for thrombocytopenia in humans, anagrelide has been used recently small number patients with thrombocytosis and myeloproliferative disorders. Platelet count well controlled the large majority patients, only minimal side effects were observed. Patients Eight (5 essential thrombocythemia, 2 chronic granulocytic leukemia, 1 idiopathic myelofibrosis) received (induction dose 4 mg/die; mean maintenance observation time 26 weeks). Complete blood counts determined times during first month, subsequently every month. "In "ex function studied before after 10 days therapy. Results reduced maintained below 500 x 10(9)/L 5 8 patients. Headache, palpitation/tachycardia, gastrointestinal symptoms decrease hemoglobin effects. did not modify leukocyte or vivo"/"ex function. Conclusions may control disorders, even when traditional drugs have failed. When required, anti-aggregating be associated anagrelide, since no effect on